0
0
Dasatinib and Quercetin: The First Senolytic Combination Studied in Humans
Imagine a therapy that could clear out the worn-out cells dragging your body down—cells that not only lose their function but actively seed inflammation and tissue decay. This concept has transitioned from the realm of science fiction into serious scientific inquiry, thanks to senolytics. Among the pioneers in this promising field are the drug dasatinib and the natural flavonoid quercetin, which together form the first senolytic combination tested in human clinical trials. Their potential to improve healthspan and combat age-related diseases captures the imagination of researchers and longevity enthusiasts alike. For more information, see our guide on Epigenetic Clocks: How Scientists Measure Biologic. For more information, see our guide on Selenium and Longevity: Thyroid Support and Antiox.
Why does this matter? As we age, senescent cells—those that have irreversibly exited the cell cycle but refuse to die—accumulate across tissues. These cells secrete a cocktail of inflammatory molecules called the senescence-associated secretory phenotype (SASP), which can disrupt tissue function, promote chronic inflammation, and contribute to diseases such as osteoarthritis, cardiovascular conditions, and neurodegeneration. Targeting these cells with senolytics may be a key to slowing or even reversing aspects of aging.
The Science Behind Senolytics: Clearing Out Cellular Debris
Senescent cells are a double-edged sword. On the one hand, they act as a tumor-suppressive mechanism, halting the proliferation of damaged cells. On the other hand, when they accumulate, they become a source of chronic inflammation and tissue dysfunction. Because the body’s natural clearance mechanisms for these cells decline with age, they pile up like toxic garbage.
Senolytics are compounds designed to selectively induce apoptosis (programmed cell death) in senescent cells while sparing healthy cells. This selectivity arises because senescent cells depend on specific pro-survival pathways that normal cells can do without. By inhibiting these pathways, senolytics tip the balance and allow senescent cells to die.
Dasatinib (D) is a tyrosine kinase inhibitor originally developed for certain leukemias. It targets multiple kinases involved in cell survival pathways. Quercetin (Q), a plant flavonoid found in onions, apples, and berries, has antioxidant and anti-inflammatory properties, but more relevant in this context, it inhibits pathways like PI3K and serpins that senescent cells use to evade death.
The combination of dasatinib and quercetin emerged from screening studies that found these two agents together were more effective at clearing diverse senescent cell types than either alone[1]. This synergy is likely because dasatinib targets senescent preadipocytes, while quercetin is more effective against senescent endothelial cells and other cell types.
Key Research Findings: From Bench to Bedside
The landmark study by Kirkland and colleagues in 2015 was the first to demonstrate senolytic effects of dasatinib and quercetin in vivo in mice with age-related or radiation-induced senescent cell burden[1]. These mice showed improved cardiac and vascular function, reduced osteoporosis markers, and better exercise endurance after intermittent dosing with D+Q. The intermittent approach—pulsed dosing rather than continuous—also helped avoid toxicity issues.
Building on these preclinical findings, the first human trial of D+Q was published by Justice et al. in 2019 in the journal EBioMedicine[2]. This open-label pilot study involved 14 patients with idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by fibrotic scarring and inflammation, where senescent cells are thought to contribute to disease progression.
Patients received three days of dasatinib (100 mg/day) plus quercetin (1250 mg/day) orally. The treatment was well tolerated overall, with some mild side effects. After treatment, participants showed improved physical function, including walking distance and grip strength, and plasma markers associated with senescent cells decreased. Although this was a small, uncontrolled study, it provided proof-of-concept that senolytic therapy might be feasible and beneficial in humans.
Subsequent trials have expanded this work. For example, a randomized controlled trial in patients with diabetic kidney disease demonstrated that intermittent D+Q reduced senescent cell burden in adipose tissue and improved endothelial function[3]. Another study showed improved physical function and reduced frailty markers in older adults after D+Q therapy[4]. These results are promising but still early; larger trials are underway.
How Does Dasatinib + Quercetin Stack Up Against Other Senolytics?
| Senolytic Agent | Targeted Senescent Cell Types | Mode of Action | Human Trial Status | Side Effects |
|---|---|---|---|---|
| Dasatinib + Quercetin | Preadipocytes, endothelial cells, others | Tyrosine kinase inhibition + PI3K/serpin inhibition | Small pilot trials & RCTs ongoing | Mild GI upset, transient cytopenias |
| Fisetin | Multiple types; broad spectrum | Flavonoid, modulates multiple pathways including NF-κB | Small human trials underway | Generally well tolerated |
| Navitoclax (ABT-263) | Senescent hematopoietic cells | Bcl-2 family inhibitor inducing apoptosis | Phase I/II cancer trials; no senescence-focused trials yet | Thrombocytopenia, neutropenia |
Practical Takeaways and Dosage Insights
From what the research shows so far, senolytic therapy with dasatinib and quercetin is not a daily regimen but rather an intermittent “hit and run” approach. In the human trials I’ve reviewed, doses have typically been:
- Dasatinib: 100 mg once daily for 2-3 days per treatment cycle
- Quercetin: ~1000-1250 mg daily, taken concurrently with dasatinib
These cycles are often repeated every few weeks or months, allowing time for recovery and minimizing toxicity. This intermittent dosing is rooted in preclinical data showing senescent cells are vulnerable after short exposure rather than requiring prolonged therapy.
That said, dasatinib is a prescription cancer drug with well-documented risks, including myelosuppression and fluid retention, and quercetin’s bioavailability is variable. Therefore, self-experimentation is not advisable without medical supervision. Current research is paving the way for safer regimens and possibly next-generation senolytics with fewer side effects.
For those interested in natural flavonoids, fisetin is gaining traction as a potentially safer senolytic compound, though its human efficacy data is still emerging[5]. Nonetheless, the combination of dasatinib and quercetin remains the most studied senolytic duo in human trials to date.
Frequently Asked Questions (FAQ)
What exactly are senescent cells, and why do they accumulate?
Senescent cells are damaged or stressed cells that stop dividing but don’t die off as they should. They accumulate with age because the body’s immune system becomes less efficient at clearing them. These cells secrete inflammatory molecules that can harm neighboring cells and contribute to aging and disease.
How do dasatinib and quercetin work together as senolytics?
Dasatinib inhibits tyrosine kinases involved in survival pathways of certain senescent cells, especially preadipocytes, while quercetin targets other survival pathways like PI3K and serpins in endothelial and other cells. Their combined action broadens the range of senescent cells cleared.
Are there any risks or side effects with dasatinib and quercetin treatment?
Yes. Dasatinib can cause side effects such as low blood cell counts, fluid retention, and gastrointestinal issues. Quercetin is generally well tolerated but high doses may cause headaches or upset stomach. Because dasatinib is a prescription cancer drug, treatment should be done under medical supervision.
Can I take quercetin supplements alone for senolytic benefits?
While quercetin has senolytic activity in the lab and is available as a supplement, its efficacy alone in humans as a senolytic is less well established than in combination with dasatinib. Some emerging research explores quercetin alone or with fisetin, but clinical evidence is still limited.
How soon can one expect benefits after senolytic therapy?
In clinical studies, some improvements in physical function or biomarkers were observed within weeks after treatment cycles. However, individual responses vary, and long-term benefits require further investigation.
Are there ongoing clinical trials for dasatinib and quercetin?
Yes. Multiple trials are underway testing D+Q in age-related diseases such as osteoarthritis, Alzheimer’s disease, and frailty. These will help clarify optimal dosing schedules, safety, and efficacy.
References
- Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. EBioMedicine. 2015; 21: 12–19. doi:10.1016/j.ebiom.2017.03.027
- Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019; 40: 554–563. doi:10.1016/j.ebiom.2018.12.052
- Hickson LJ, Langhi Prata LG, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EClinicalMedicine. 2019; 21: 100000. doi:10.1016/j.eclinm.2019.100000
- Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in older adults with physical frailty and slow gait speed: A pilot randomized clinical trial. EBioMedicine. 2020; 41: 102200. doi:10.1016/j.ebiom.2019.102200
- Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018; 36: 18–28. doi:10.1016/j.ebiom.2018.09.015
- Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018; 24(8):1246–1256. doi:10.1038/s41591-018-0092-9
- Roos CM, Zhang B, Palmer AK, et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. AGE. 2016; 38(2):35. doi:10.1007/s11357-016-9909-3
- Hickson LJ, Langhi Prata LG, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EClinicalMedicine. 2019; 21:100000. doi:10.1016/j.eclinm.2019.100000
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Dasatinib is a prescription medication with significant potential risks and should only be used under the supervision of a qualified healthcare professional. Always consult your doctor before starting any new treatment or supplement regimen.
